Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Fredrik G Oberg, Karin Tunblad, Ana Slipicevic, Richard Bethell and Mark R Albertella | ||||||||||||
Title | MIV-818 stimulates an antitumor immune response in vitro and enhances the effects of pembrolizumab | ||||||||||||
|
|||||||||||||
URL | https://mct.aacrjournals.org/content/18/12_Supplement/C056.abstract | ||||||||||||
Abstract Text | Mol Cancer Ther 2019;18(12 Suppl):Abstract nr C056. |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MIV-818 | MIV818|MIV 818 | MIV-818 is a prodrug that is hydrolyzed in hepatocytes to troxacitabine triphosphate (TRX-TP), which may have immune modulating and anti-tumor effects (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr C056.). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|